Halozyme Therapeutics (HALO) Tops Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $115.13 --0%
EPS Growth %: +30.8%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: +30.8%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.19), $0.04 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $25.6 million versus the consensus estimate of $30.42 million.
GUIDANCE:
Halozyme Therapeutics sees FY2018 revenue of $150-160 million, versus the consensus of $127.8 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- KeyBanc Sees 'A Potential Catalyst for Earnings Growth and Value Creation' for Acadia Realty Trust (AKR)
- Worthington Industries (WOR) Tops Q1 EPS by 7c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
